LUN17-139 study investigators

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals. The LUN17-139 study investigators refers to the clinical research group for the PACIFIC-2 trial, a Phase 3 study sponsored by AstraZeneca. This trial evaluated the efficacy of durvalumab (Imfinzi) when administered concurrently with definitive chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer. Although the PACIFIC-2 trial did not meet its primary endpoint of progression-free survival, AstraZeneca remains a leader in the oncology space with a broad portfolio of approved therapies. The company operates across several main therapeutic areas, including Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.